Cetuximab
- Generic Name
- Cetuximab
- Brand Names
- Erbitux
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 205923-56-4
- Unique Ingredient Identifier
- PQX0D8J21J
- Background
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelia...
- Indication
Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for r...
- Associated Conditions
- Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Metastatic Colorectal Cancer (CRC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Regionally Advanced Squamous Cell Carcinoma of the Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
- Target Recruit Count
- 156
- Registration Number
- NCT00169247
- Locations
- 🇫🇷
Centre Oscar Lambret, Lille, France
🇫🇷Centre René Gauducheau, Nantes, France
🇫🇷CHU de Tours, Tours, France
Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2009-07-22
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 53
- Registration Number
- NCT00165334
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2014-11-10
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 19
- Registration Number
- NCT00165490
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 40
- Registration Number
- NCT00162110
- Locations
- 🇺🇸
Local Institution, Cincinnati, Ohio, United States
Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2009-02-27
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 135
- Registration Number
- NCT00153998
- Locations
- 🇩🇪
Kreiskrankenhaus Aschersleben, Aschersleben, Germany
🇩🇪Allgemeines Krankenhaus Celle, Celle, Germany
🇩🇪Westpfalz-Klinikum GmbH Innere Medizin I, Kaiserslautern, Germany
Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 1221
- Registration Number
- NCT00154102
- Locations
- 🇫🇷
Research Sites, Nantes, France
🇬🇧Research Site, Sutton, United Kingdom
Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT00148109
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2014-03-18
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT00142428
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00134069
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸University of Colorado at Denver Health Sciences Center, Aurora, Colorado, United States
Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-08-16
- Last Posted Date
- 2015-05-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 43
- Registration Number
- NCT00130689
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.